Madrigal Pharmaceuticals Inc (MDGL)
220.06
+2.89
(+1.33%)
USD |
NASDAQ |
May 17, 16:00
220.06
0.00 (0.00%)
After-Hours: 20:00
Madrigal Pharmaceuticals Research and Development Expense (Annual): 272.35M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 272.35M |
| December 31, 2022 | 245.44M |
| December 31, 2021 | 205.16M |
| December 31, 2020 | 184.81M |
| December 31, 2019 | 72.32M |
| December 31, 2018 | 25.39M |
| December 31, 2017 | 24.39M |
| December 31, 2016 | 15.93M |
| December 31, 2015 | 2.427M |
| December 31, 2014 | 68.20M |
| December 31, 2013 | 71.86M |
| December 31, 2012 | 49.41M |
| Date | Value |
|---|---|
| December 31, 2011 | 41.46M |
| December 31, 2010 | 40.25M |
| December 31, 2009 | 51.05M |
| December 31, 2008 | 81.58M |
| December 31, 2007 | 52.02M |
| December 31, 2006 | 50.50M |
| December 31, 2005 | 59.90M |
| December 31, 2004 | 38.14M |
| December 31, 2003 | 24.34M |
| December 31, 2002 | 7.292M |
| December 31, 2001 | 0.277M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
72.32M
Minimum
2019
272.35M
Maximum
2023
196.02M
Average
205.16M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Viking Therapeutics Inc | 63.81M |
| Eli Lilly and Co | 9.313B |
| Akero Therapeutics Inc | 141.80M |
| 89bio Inc | 122.23M |
| Geron Corp | 125.05M |